Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: A review

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Amini, Arya ^a   Yeh, Norman ^a   Gaspar, Laurie E ^a   Kavanagh, Brian ^a   Karam, Sana D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

NSCLC; Re irradiation; SBRT; Toxicity

Indexed keywords

ACUTE TOXICITY; BRACHIAL PLEXUS NEUROPATHY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; ERYTHEMA; ESOPHAGITIS; ESOPHAGUS INJURY; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CANCER; LUNG TOXICITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION SICKNESS; REPEAT PROCEDURE; REVIEW; RIB FRACTURE; SCAR FORMATION; SKIN TOXICITY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; THORAX PAIN; TREATMENT OUTCOME; TUMOR VOLUME; FEMALE; LUNG NEOPLASMS; MALE; PROCEDURES; RADIOSURGERY; RADIOTHERAPY; TUMOR RECURRENCE;

FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY; RADIOTHERAPY;

EID: 84907914142     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-210     Document Type: Review

References (52)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Jeremic B, Shibamoto Y, Acimovic L, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G. Second cancers occurring in patients with early stage non-small-cell lung cancer treated with chest radiation therapy alone. J Clin Oncol 2001, 19:1056-1063.
3. Carr SR, Schuchert MJ, Pennathur A, Wilson DO, Siegfried JM, Luketich JD, Landreneau RJ. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg 2012, 143:390-397. 10.1016/j.jtcvs.2011.10.023, 22169444.
4. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83:417-423. 10.1093/jnci/83.6.417, 1847977.
5. Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry 1983, 46:797-803. 10.1136/jnnp.46.9.797, 1027560, 6352865.
6. Zhang J, Yang F, Li B, Liu J, Huang W, Wang D, Yi Y, Wang J. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011, 81:e305-e316. 10.1016/j.ijrobp.2011.04.034, 21658853.
7. Martel MK, Ten Haken RK, Hazuka MB, Kessler ML, Strawderman M, Turrisi AT, Lawrence TS, Fraass BA, Lichter AS. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999, 24:31-37. 10.1016/S0169-5002(99)00019-7, 10403692.
8. Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008, 26:4001-4011. 10.1200/JCO.2007.15.3312, 18711191.
9. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasaw K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101:1623-1631. 10.1002/cncr.20539, 15378503.
10. Kavanagh BD, Timmerman RD. Stereotactic body radiation therapy 2005, Philadelphia: Lippincott Williams & Wilkins.
11. Noble J, Ellis PM, Mackay JA, Evans WK. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006, 1:1042-1058. 10.1097/01243894-200611000-00021, 17409993.
12. Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT, Argiris A, Grandis JR, Lai SY. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009, 75:1493-1500. 10.1016/j.ijrobp.2008.12.075, 19464819.
13. Roh KW, Jang JS, Kim MS, Sun DI, Kim BS, Jung SL, Kang JH, Yoo EJ, Yoon SC, Jang HS, Chung SM, Kim YS. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 74:1348-1355. 10.1016/j.ijrobp.2008.10.013, 19117695.
14. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007, 25:947-952. 10.1200/JCO.2006.09.7469, 17350943.
15. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946-1955. 10.1378/chest.124.5.1946, 14605072.
16. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:117-125. 10.1016/j.ijrobp.2006.04.013, 16765528.
17. Nagata Y, Takayama K, Matsuo Y, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431. 10.1016/j.ijrobp.2005.05.034, 16169670.
18. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839. 10.1200/JCO.2006.07.5937, 17050868.
19. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076. 10.1001/jama.2010.261, 2907644, 20233825.
20. Mantel F, Flentje M, Guckenberger M. Stereotactic body radiation therapy in the re-irradiation situation-a review. Radiat Oncol 2013, 8:7. 10.1186/1748-717X-8-7, 3552718, 23289496.
21. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 2010, 78:1387-1393. 10.1016/j.ijrobp.2009.09.070, 3401019, 20381271.
22. Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW, Diehn M. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol 2012, 7:1462-1465. 10.1097/JTO.0b013e31825f22ce, 22895143.
23. Reyngold M, Wu AJ, McLane A, Zhang Z, Hsu M, Stein NF, Zhou Y, Ho AY, Rosenzweig KE, Yorke ED, Rimner A. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol 2013, 8:99. 10.1186/1748-717X-8-99, 3651392, 23617949.
24. Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer 2008, 9:217-221. 10.3816/CLC.2008.n.032, 18650169.
25. Ester EC, Jones DA, Vernon MR, Yuan J, Weaver RD, Shanley RM, Andrade RS, Cho LC. Lung reirradiation with stereotactic body radiotherapy (SBRT). J Radiosurg & SBRT 2013, 2:325-331.
26. Seung SK, Solhjem M. Salvage SBRT for previously irradiated lung cancer. J Cancer Ther 2011, 2:190-195.
27. Trovo M, Minatel E, Durofil E, Polasel J, Avanzo M, Baresic T, Bearz A, Del Conte A, Franchin G, Gobitti C, Rumeileh IA, Trovo MG. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014, 88:1114-1119. 10.1016/j.ijrobp.2014.01.012, 24661664.
28. Simone CB, Wildt B, Haas AR, Pope G, Rengan R, Hahn SM. Stereotactic body radiation therapy for lung cancer. Chest 2013, 143:1784-1790. 10.1378/chest.12-2580, 23732589.
29. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012, 84:1017-1023. 10.1016/j.ijrobp.2012.02.020, 3612879, 22543216.
30. Evans JD, Gomez DR, Amini A, Rebueno N, Allen PK, Martel MK, Rineer JM, Ang KK, McAvoy S, Cox JD, Komaki R, Welsh JW. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 2013, 106:327-332. 10.1016/j.radonc.2013.02.002, 3921976, 23453540.
31. Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y, Kanazawa S. Radiofrequency ablation for early-stage nonsmall cell lung cancer. Biomed Res Int 2014, 2014:152087. 4065773, 24995270.
32. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, Danna M, Inoue T, Deniaud-Alexandre E, Schipani S, Watanabe N, Dondi M, Jeremic B. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009, 91:85-94. 10.1016/j.radonc.2008.11.008, 19100641.
33. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006, 81:209-225. 10.1016/j.radonc.2006.09.011, 17064802.
34. Wang YC, Tseng HL, Lin YH, Kao CH, Huang WC, Huang TC. Improvement of internal tumor volumes of non-small cell lung cancer patients for radiation treatment planning using interpolated average CT in PET/CT. PLoS One 2013, 8:e64665. 10.1371/journal.pone.0064665, 3655997, 23696903.
35. Pommier P, Touboul E, Chabaud S, Dussart S, Le Pechoux C, Giammarile F, Carrie C. Impact of (18) F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: a prospective multicenter study. AJR Am J Roentgenol 2010, 195:350-355. 10.2214/AJR.09.3981, 20651189.
36. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A. Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 2013, 31:3823-3830. 10.1200/JCO.2012.47.5947, 24043740.
37. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, Yang DJ, Endo K, Podoloff DA. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995, 36:788-793.
38. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59:78-86. 10.1016/j.ijrobp.2003.10.044, 15093902.
39. Keall P. 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 2004, 14:81-90. 10.1053/j.semradonc.2003.10.006, 14752736.
40. Christodoulou M, Bayman N, McCloskey P, Rowbottom C, Faivre-Finn C. New radiotherapy approaches in locally advanced non-small cell lung cancer. Eur J Cancer 2014, 50:525-534. 10.1016/j.ejca.2013.11.027, 24333095.
41. Gunderson LL, Tepper J. Clinical Radiation Oncology 2011, Philadelphia: Elsevier Health Sciences, 3.
42. Wulf J, Hadinger U, Oppitz U, Thiele W, Flentje M. Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. Radiother Oncol 2003, 66:141-150. 10.1016/S0167-8140(02)00372-9, 12648785.
43. Vinogradskiy Y, Castillo R, Castillo E, Tucker SL, Liao Z, Guerrero T, Martel MK. Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes. Int J Radiat Oncol Biol Phys 2013, 86:366-371. 10.1016/j.ijrobp.2013.01.004, 3875308, 23474113.
44. De Ruysscher D, Belderbos J, Reymen B, van Elmpt W, van Baardwijk A, Wanders R, Hoebers F, Vooijs M, Ollers M, Lambin P. State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clin Lung Cancer 2013, 14:89-95. 10.1016/j.cllc.2012.06.006, 22853981.
45. Gressen EL, Werner-Wasik M, Cohn J, Topham A, Curran WJ. Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol 2000, 23:160-163. 10.1097/00000421-200004000-00011, 10776977.
46. Jeremic B, Videtic GM. Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys 2011, 80:969-977. 10.1016/j.ijrobp.2011.01.069, 21489714.
47. Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol 2012, 7:33. 10.1186/1748-717X-7-33, 3337239, 22420631.
48. Feld R, Abratt R, Graziano S, Jassem J, Lacquet L, Ninane V, Paesmans M, Rocmans P, Schiepers C, Stahel R, Stephens R. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 1997, 17(Suppl 1):S3-S10.
49. Nguyen LN, Komaki R, Allen P, Schea RA, Milas L. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review. Int J Radiat Oncol Biol Phys 1999, 44:1053-1056. 10.1016/S0360-3016(99)00130-3, 10421538.
50. McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995, 31:1187-1203. 10.1016/0360-3016(94)00429-O, 7713782.
51. Senthi S, Dahele M, van de Ven PM, Slotman BJ, Senan S. Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques. Radiother Oncol 2013, 109:77-81. 10.1016/j.radonc.2013.08.034, 24060174.
52. Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 2011, 6:1221-1228. 10.1097/JTO.0b013e318219aac5, 21623237.